賽隆藥業(002898.SZ):進一步聚焦主業 擬轉讓湖南勝隆置業100%股權
格隆匯5月17日丨賽隆藥業(002898.SZ)公佈,為進一步聚焦主業,整合資源,公司於2021年5月17日召開了第三屆董事會第三次會議,審議通過了《關於轉讓全資子公司湖南勝隆置業有限公司100%股權的議案》,同意公司將持有的全資子公司湖南勝隆置業有限公司(“湖南勝隆”)100%的股權轉讓給受讓方吳固林,轉讓價格為1023.88萬元,董事會授權公司經營層辦理與本次股權轉讓相關的事宜。公司將與吳固林簽訂《股權轉讓協議》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.